---
title: "Imugene Issues Additional Unquoted Options Under Capital Management Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278823057.md"
description: "Imugene Limited has issued additional unquoted options under ASX code IMUAJ, each exercisable at $0.86 and expiring on 30 June 2028. A total of 2,872 options were issued as part of its capital management plan, aimed at financing or incentivizing staff without diluting existing shareholders. This move does not affect the company's quoted share capital structure. The latest analyst rating for Imugene stock (AU:IMU) is a Sell with a price target of A$0.22. The company focuses on developing cancer immunotherapies and has a market cap of A$73.95M."
datetime: "2026-03-12T05:18:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278823057.md)
  - [en](https://longbridge.com/en/news/278823057.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278823057.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278823057.md) | [繁體中文](https://longbridge.com/zh-HK/news/278823057.md)


# Imugene Issues Additional Unquoted Options Under Capital Management Plan

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Imugene ( (AU:IMU) ) has shared an update.

Imugene Limited has notified the market of the issue of additional unquoted options under ASX code IMUAJ, each exercisable at $0.86 and expiring on 30 June 2028. A total of 2,872 options were issued across two tranches on 4 and 5 March 2026, as part of previously announced transactions and are not intended to be quoted on the ASX.

The new options expand Imugene’s pool of unquoted equity instruments used for financing or incentivising staff, directors, or partners, without immediately diluting existing shareholders through listed securities. This move reflects ongoing execution of the company’s capital management plans but does not alter its quoted share capital structure in the near term.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.22 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

**More about Imugene**

Imugene Limited is an ASX-listed biotechnology company focused on developing cancer immunotherapies. The company issues options and other equity-linked securities as part of its capital management and incentive arrangements for stakeholders in the Australian market.

**Average Trading Volume:** 1,404,984

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$73.95M

For an in-depth examination of IMU stock, go to TipRanks’ Overview page.

### Related Stocks

- [Imugene Limited (IMU.AU)](https://longbridge.com/en/quote/IMU.AU.md)

## Related News & Research

- [Imugene Confirms EGM Date and Updates Securities Purchase Plan Timetable](https://longbridge.com/en/news/279688245.md)
- [Imugene Secures $12m Placement in $20m Capital Raise to Fund Azer-cel Trial](https://longbridge.com/en/news/278647042.md)
- [MaxiPARTS Sets DRP Price at A$1.94 for December Half-Year Dividend](https://longbridge.com/en/news/279182474.md)
- [Vintage Energy plans major pro rata equity and options issue](https://longbridge.com/en/news/279335701.md)
- [WT Financial Group Options Expire Unexercised, Trimming Potential Dilution](https://longbridge.com/en/news/279179021.md)